Cite
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
MLA
McGuire, Darren K., et al. “Effects of Empagliflozin on First and Recurrent Clinical Events in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Secondary Analysis of the EMPA-REG OUTCOME Trial.” The Lancet. Diabetes & Endocrinology, vol. 8, no. 12, Dec. 2020, pp. 949–59. EBSCOhost, https://doi.org/10.1016/S2213-8587(20)30344-2.
APA
McGuire, D. K., Zinman, B., Inzucchi, S. E., Wanner, C., Fitchett, D., Anker, S. D., Pocock, S., Kaspers, S., George, J. T., von Eynatten, M., Johansen, O. E., Jamal, W., Mattheus, M., Elsasser, U., Hantel, S., & Lund, S. S. (2020). Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. The Lancet. Diabetes & Endocrinology, 8(12), 949–959. https://doi.org/10.1016/S2213-8587(20)30344-2
Chicago
McGuire, Darren K, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, David Fitchett, Stefan D Anker, Stuart Pocock, et al. 2020. “Effects of Empagliflozin on First and Recurrent Clinical Events in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Secondary Analysis of the EMPA-REG OUTCOME Trial.” The Lancet. Diabetes & Endocrinology 8 (12): 949–59. doi:10.1016/S2213-8587(20)30344-2.